LS Investment Advisors LLC maintained its stake in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, Holdings Channel reports. The fund owned 1,369 shares of the medical device company’s stock at the end of the second quarter. LS Investment Advisors LLC’s holdings in DexCom were worth $100,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Sit Investment Associates Inc. raised its stake in DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock valued at $2,025,000 after buying an additional 14,700 shares during the period. Morgan Stanley raised its stake in DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock valued at $177,336,000 after buying an additional 319,631 shares during the period. DUPONT CAPITAL MANAGEMENT Corp bought a new stake in DexCom during the first quarter valued at approximately $270,000. Swiss National Bank raised its stake in DexCom by 28.4% in the first quarter. Swiss National Bank now owns 299,500 shares of the medical device company’s stock valued at $25,377,000 after buying an additional 66,200 shares during the period. Finally, Teachers Advisors LLC raised its stake in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock valued at $11,018,000 after buying an additional 7,050 shares during the period.

Shares of DexCom, Inc. (NASDAQ:DXCM) traded down 0.29% during mid-day trading on Friday, hitting $69.60. The stock had a trading volume of 940,650 shares. The stock has a 50 day moving average price of $71.12 and a 200-day moving average price of $75.17. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38. The company’s market cap is $6.02 billion.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.24) EPS. On average, equities analysts expect that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (NASDAQ:DXCM) Position Held by LS Investment Advisors LLC” was published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/dexcom-inc-nasdaqdxcm-position-held-by-ls-investment-advisors-llc.html.

DXCM has been the topic of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 target price on shares of DexCom in a report on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $98.00 price objective on DexCom and gave the company a “buy” rating in a report on Wednesday, May 3rd. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Piper Jaffray Companies reissued an “overweight” rating and issued a $78.00 price objective on shares of DexCom in a report on Monday, May 22nd. Finally, TheStreet raised DexCom from a “d” rating to a “c-” rating in a report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $87.00.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 8,649 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the sale, the chief executive officer now owns 347,329 shares in the company, valued at approximately $23,753,830.31. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,375 shares of company stock worth $2,549,351. Insiders own 1.70% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.